SEC/VC  Omega Funds

     Office Locations:

185 Dartmouth Street, Suite 502
Boston, MA 02116



  • Early
  • Expansion
  • Growth



  • Life Sciences & Healthcare



    Omega Funds was established in 2004, and manages six funds with investments across Europe, North America and the Far East. Omega invests in both public and private companies, completing investments across all healthcare sectors, including biotech, medtech, diagnostics, services and healthcare IT since inception. The firm considers investments in three areas: Primary Venture - Investing in early-, mid- and late-stage private companies developing transformational technologies and products to address unmet needs in healthcare and biotechnology; Publics - Supporting the capital needs of publicly traded, small-cap life sciences companies with short or medium term clinical milestones, usually via PIPEs or IPOs; and Direct Secondaries - Providing partial or total liquidity as well as follow-on capital, to existing shareholders in single assets or portfolios of companies.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Anne-Mari Paster CFO
    Claudio Nessi Managing Director
    Dina Chaya PhD Partner
    Francesco Draetta CFA, FRM, CAIA Principal
    Huge Beekman Principal


    Recent Funding Events (trailing 12 months):







      Morphic Therapeutic



      Series B


      Kronos Bio








      Series A


      Prevail Therapeutics



      Series A


      Senti Biosciences





    Portfolio companies include:


    Recent News: